文献速递重症综合管理与镇静镇痛

重症监护谵妄试验中的复合终点

Composite Endpoints in Critical Care Delirium Trials.
PubMed 文献 · Crit Care Med · 2026-11-11
一句话结论谵妄持续时间因谵妄发作性及昏迷、死亡竞争事件而难以直接分析,重症谵妄试验可采用谵妄和昏迷无天数或死亡排序复合终点,但此类终点尚未被严格评估。

谵妄是危重患者常见的异常精神状态,与死亡等不良结局相关,谵妄持续时间越长,幸存者长期认知损害越重。以谵妄持续时间为终点面临发作性和昏迷、死亡竞争事件导致的偏倚。谵妄试验因此采用两种复合终点:谵妄和昏迷无天数(对幸存者和非幸存者均定义为无谵妄或昏迷的存活天数),以及将死亡列为最差状态、对幸存者排序无谵妄或昏迷存活天数的替代复合终点。上述复合终点迄今尚未被严格评估。本文利用MENDS试验数据说明复合终点的使用、定义治疗效应及临床可解释性,并展示治疗效应随时间累积的可视化方法,据此提出实用建议。

要点

  • 谵妄持续时间因谵妄的发作性及昏迷、死亡竞争事件而难以在随机试验中直接测量和分析,可导致偏倚。
  • 谵妄和昏迷无天数对幸存者和非幸存者均定义为无谵妄或昏迷的存活天数,是谵妄试验采用的复合终点之一。
  • 另一种复合终点将死亡列为最差状态,对幸存者排序无谵妄或昏迷的存活天数。
  • 上述复合终点迄今尚未被严格评估,本文利用MENDS试验数据说明其定义、治疗效应解释及可视化方法。
  • 作者基于分析提出重症谵妄试验使用复合终点的实用建议,并可扩展至依赖类似复合终点的其他随机试验。

适用人群与场景

  • 重症监护病房中的危重患者,发生谵妄者。

诊断标准与关键阈值

  • 谵妄定义为注意力和意识急性改变的异常精神状态。

研究设计与关键结果

  • 本文利用最大化靶向镇静疗效与减少神经功能障碍(MENDS)试验的数据,说明重症谵妄试验中复合终点的使用、治疗效应定义及临床可解释性,并展示治疗效应在随访期间累积的可视化方法。

证据类型、等级与局限

  • 证据类型:基于MENDS试验数据的综述性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于上述分析提出的复合终点使用实用建议可用于重症谵妄试验,并可扩展至依赖类似复合终点的其他随机试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Delirium is an abnormal mental status, commonly occurring among critically ill patients, in which a person's attention and awareness change acutely. Delirium is associated with negative outcomes, including death. Furthermore, a longer duration of delirium is associated with long-term cognitive impairment in survivors of critical illness. Hence, there is a need for novel interventions that reduce the duration of delirium; however, measuring and analyzing "duration of delirium" as an endpoint in randomized trials is challenging due to the episodic nature of delirium and the competing events of coma and death, which can bias analyses of duration of delirium. Given these challenges, delirium trials have adopted one of two composite endpoints: delirium- and coma-free days, defined as the number of days alive without delirium or coma for both survivors and nonsurvivors, and an alternative composite that ranks death as the worst state and orders days alive without delirium or coma among survivors. To date, these composite endpoints have not been rigorously evaluated. Hence, herein we use data from the Maximizing Efficacy of Targeted Sedation and Reducing Neurologic Dysfunction (MENDS) trial to motivate the use of composite endpoints in critical care delirium trials, discuss how to define the effect of treatment on each composite endpoint and their clinical interpretability, and present a method for visualizing how the treatment effects accrue over the course of follow-up. Based on these analyses, we provide practical recommendations for the use of composite endpoints in critical care delirium trials, which could be extended to other randomized trials that rely on similar composite endpoints.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Smith BB, Pandharipande PP, Ely EW, et al. Composite Endpoints in Critical Care Delirium Trials. Crit Care Med. 2026. PMID: 43012619. doi:10.1097/CCM.0000000000007420

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。